Bioceros Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 28

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.6M

Bioceros General Information

Description

Operator of a biotechnology company intended to offer preclinical development of monoclonal antibodies. The company's services mainly focus on early pre-clinical development of recombinant proteins, with an emphasis on monoclonal antibodies, enabling customers to get access to completely integrated program from DNA to drug product to advance their medicinal product and help patients in need.

Contact Information

Website
www.bioceros.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Yalelaan 46
  • Alexander Numan Building, 2nd floor
  • 3584 CM Utrecht
  • Netherlands
+31 088
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Polpharma Biologics Group
Vertical(s)
Life Sciences
Corporate Office
  • Yalelaan 46
  • Alexander Numan Building, 2nd floor
  • 3584 CM Utrecht
  • Netherlands
+31 088

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bioceros Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 30-Jun-2016 $3.6M Completed Generating Revenue
5. Merger/Acquisition 09-Sep-2015 Completed Generating Revenue
4. IBO 17-Feb-2011 Completed Generating Revenue
3. Grant 12-Jan-2011 Completed Generating Revenue
2. Early Stage VC 12-Sep-2008 Completed Startup
1. Early Stage VC Completed Startup
To view Bioceros’s complete valuation and funding history, request access »

Bioceros Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • Pending

  • Expiring in next 12 mo

Bioceros Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150132288-A1 Anti-cd134 (ox40) antibodies and uses thereof Active 16-Sep-2011
US-20170051069-A1 Anti-cd134 (ox40) antibodies and uses thereof Inactive 16-Sep-2011
US-9475880-B2 Anti-cd134 (ox40) antibodies and uses thereof Inactive 16-Sep-2011
WO-2013038191-A2 Anti-cd134 (ox40) antibodies and uses thereof Inactive 16-Sep-2011
WO-2013038191-A3 Anti-cd134 (ox40) antibodies and uses thereof Inactive 16-Sep-2011 C07K16/2878
To view Bioceros’s complete patent history, request access »

Bioceros Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bioceros Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioGeneration Ventures Venture Capital Minority
EPIRUS Biopharmaceuticals Corporation Majority
Forbion Venture Capital Minority
Thuja Capital Management Venture Capital Minority
Utrecht Holdings Not-For-Profit Venture Capital Minority
To view Bioceros’s complete investors history, request access »

Bioceros Investments & Acquisitions (2)

Bioceros’s most recent deal was a Merger/Acquisition with Cilian. The deal was made on 16-Sep-2005.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cilian 16-Sep-2005 Merger/Acquisition Drug Discovery
Broteio Joint Venture Drug Discovery
To view Bioceros’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Bioceros FAQs

  • When was Bioceros founded?

    Bioceros was founded in 2003.

  • Where is Bioceros headquartered?

    Bioceros is headquartered in Utrecht, Netherlands.

  • What is the size of Bioceros?

    Bioceros has 28 total employees.

  • What industry is Bioceros in?

    Bioceros’s primary industry is Drug Discovery.

  • Is Bioceros a private or public company?

    Bioceros is a Private company.

  • What is the current valuation of Bioceros?

    The current valuation of Bioceros is .

  • What is Bioceros’s current revenue?

    The current revenue for Bioceros is .

  • Who are Bioceros’s investors?

    BioGeneration Ventures, EPIRUS Biopharmaceuticals, Forbion, Thuja Capital Management, and Utrecht Holdings have invested in Bioceros.

  • When was Bioceros acquired?

    Bioceros was acquired on 30-Jun-2016.

  • Who acquired Bioceros?

    Bioceros was acquired by Polpharma Biologics Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process